ライフサイエンスコーパス: granulomatous disease

1 the oxidative burst in patients with chronic granulomatous disease.

2 olunteers with that in patients with chronic granulomatous disease.

3 edictor of survival in patients with chronic granulomatous disease.

4 linked to survival in patients with chronic granulomatous disease.

5 h X-linked (NOX2) or autosomal (p47) chronic granulomatous disease.

6 primary immunodeficiency other than chronic granulomatous disease.

7 evere combined immune deficiency and chronic granulomatous disease.

8 -two percent practice in an area endemic for granulomatous disease.

9 Sarcoidosis is a heterogeneous multisystem granulomatous disease.

10 ity, lymphoid proliferation, malignancy, and granulomatous disease.

11 ciation of autoimmune disorders with chronic granulomatous disease.

12 transplantation, advanced AIDS, and chronic granulomatous disease.

13 ociation of autoimmune diseases with chronic granulomatous disease.

14 from eosinophils from a patient with chronic granulomatous disease.

15 rophils from a patient with X-linked chronic granulomatous disease.

16 ifungal agents in the prophylaxis of chronic granulomatous disease.

17 proach in the molecular treatment of chronic granulomatous disease.

18 against serious fungal infections in chronic granulomatous disease.

19 derived from patients with X-linked chronic granulomatous disease.

20 s known to have unusual virulence in chronic granulomatous disease.

21 herapy protocols being developed for chronic granulomatous disease.

22 X-linked gene CYBB, thereby causing chronic granulomatous disease.

23 iency, Wiskott-Aldrich syndrome, and chronic granulomatous disease.

24 of patients with cystic fibrosis and chronic granulomatous disease.

25 fering from cystic fibrosis (CF) and chronic granulomatous disease.

26 x)) gives rise to the known types of chronic granulomatous disease.

27 have been detected in patients with chronic granulomatous disease.

28 reas the late response is a typical Th1-type granulomatous disease.

29 s with disease and were molecular markers of granulomatous disease.

30 und to be associated with silicosis, another granulomatous disease.

31 mulated monocytes from patients with chronic granulomatous disease.

32 hagocyte functional defects, such as chronic granulomatous disease.

33 ive ROS production machinery develop chronic granulomatous disease.

34 sed by a Phellinus sp. in a boy with chronic granulomatous disease.

35 ficacious in high-risk patients with chronic granulomatous disease.

36 n-1 deficiency, CARD9 deficiency, or chronic granulomatous disease.

37 ctions, such as the genetic disorder chronic granulomatous disease.

38 es, including splenomegaly, hepatomegaly, or granulomatous disease.

39 th other lung diseases, including infectious granulomatous diseases.

40 shared mechanisms for TGF-beta1 in these two granulomatous diseases.

41 and questions about macrophage function and granulomatous diseases.

42 r the rational design of immunotherapies for granulomatous diseases.

43 mmatory disease, 15.4%; malabsorption, 5.9%; granulomatous disease, 9.7%; liver diseases and hepatiti

44 ic defect causing p47-phox-deficient chronic granulomatous disease (A47 degrees CGD) is a GT deletion

45 In the genetic disorder chronic granulomatous disease, absent oxidase function is associ

46 In chronic granulomatous disease allogeneic haemopoietic stem-cell

47 Chronic granulomatous disease, an inherited disorder of the NADP

48 this complex have been implicated in chronic granulomatous disease and Crohn's disease, highlighting

49 idity and mortality in patients with chronic granulomatous disease and cystic fibrosis.

50 therapy in genetic disorders such as chronic granulomatous disease and infectious diseases such as le

51 Chronic granulomatous disease and leukocyte adhesion deficiency

52 s in development of gene therapy for chronic granulomatous disease and leukocyte adhesion deficiency-

53 articularly beneficial in areas with endemic granulomatous disease and may improve clinical managemen

54 Patients with chronic granulomatous disease and modest residual production of

55 abscess formation in a patient with chronic granulomatous disease and review the literature on Phaeo

56 reased susceptibility to chronic infections, granulomatous disease and the lymphoproliferative predis

57 ted for other forms of PID including chronic granulomatous disease and Wiskott-Aldrich syndrome.

58 Location in an area endemic for granulomatous disease and years of experience also influ

59 ed severe combined immunodeficiency, chronic granulomatous disease, and other diseases.

60 These results have implications for granulomatous diseases, and conditions such as atheroscl

61 Sarcoidosis is a systemic granulomatous disease associated with local epithelioid

62 he frequency of fungal infections in chronic granulomatous disease, but monitoring for long-term toxi

63 acoronavirus, resulting in a lethal systemic granulomatous disease called feline infectious peritonit

64 Patients with chronic granulomatous disease can develop chronic granulomas in

65 ways of host immune cells in tuberculosis, a granulomatous disease caused by the intracellular pathog

66 ron-gamma is important for the expression of granulomatous diseases caused by infectious agents; howe

67 diates (ROIs) is the major defect in chronic granulomatous disease, causing recurrent infections and

68 unocompromising condition, including chronic granulomatous disease (CGD) (n=4), diabetes mellitus (DM

69 The rarer PID patients without chronic granulomatous disease (CGD) achieved an OS at 3 years of

70 s involved in the pathophysiology of chronic granulomatous disease (CGD) and sepsis.

71 circulating B cells in patients with chronic granulomatous disease (CGD) and those with HIV infection

72 a phenotype similar to that of human chronic granulomatous disease (CGD) and, thus, is an excellent m

73 Liver abscesses in chronic granulomatous disease (CGD) are typically difficult to t

74 in p47-phox-deficient (A47 degrees ) chronic granulomatous disease (CGD) as a result of the insertion

75 Chronic granulomatous disease (CGD) can be cured by allogeneic h

76 Chronic granulomatous disease (CGD) can result from any of four

77 fective neutrophils in patients with chronic granulomatous disease (CGD) cause susceptibility to extr

78 from a registry of 368 patients with chronic granulomatous disease (CGD) documenta shift in the most

79 ed in human patients who suffer from chronic granulomatous disease (CGD) due to defective NADPH oxida

80 Patients with chronic granulomatous disease (CGD) exhibit deficient generation

81 Patients with chronic granulomatous disease (CGD) experience immunodeficiency

82 leukocytes (PMN) from patients with chronic granulomatous disease (CGD) fail to produce microbicidal

83 educed in the blood of patients with chronic granulomatous disease (CGD) for reasons and consequences

84 Mice with X-linked chronic granulomatous disease (CGD) generated by targeted disrup

85 Although prognosis of Chronic Granulomatous Disease (CGD) has greatly improved, few st

86 Patients with chronic granulomatous disease (CGD) have a mutated NADPH complex

87 t described the clinical features of chronic granulomatous disease (CGD) in 1959.

88 ears of age) often resembles that of chronic granulomatous disease (CGD) in extent and features of co

89 Chronic granulomatous disease (CGD) is a genetic disorder of NAD

90 Chronic granulomatous disease (CGD) is a group of inherited diso

91 Chronic granulomatous disease (CGD) is a hereditary disorder of

92 Chronic granulomatous disease (CGD) is a primary immune deficien

93 Chronic granulomatous disease (CGD) is a primary immunodeficienc

94 Chronic granulomatous disease (CGD) is a primary immunodeficienc

95 Chronic granulomatous disease (CGD) is a primary immunodeficienc

96 Chronic granulomatous disease (CGD) is a primary immunodeficienc

97 Chronic granulomatous disease (CGD) is a rare congenital disorde

98 Chronic granulomatous disease (CGD) is a rare genetic disorder i

99 Chronic granulomatous disease (CGD) is a rare genetic disorder,

100 Chronic granulomatous disease (CGD) is a rare inherited disorder

101 Chronic granulomatous disease (CGD) is a rare phagocytic disorde

102 Chronic granulomatous disease (CGD) is a rare primary immunodefi

103 Chronic granulomatous disease (CGD) is an inherited deficiency o

104 Chronic granulomatous disease (CGD) is an inherited disease caus

105 Chronic granulomatous disease (CGD) is an inherited disorder cha

106 Chronic granulomatous disease (CGD) is an inherited disorder of

107 Chronic granulomatous disease (CGD) is an inherited disorder of

108 Chronic granulomatous disease (CGD) is an inherited hematologic

109 Chronic granulomatous disease (CGD) is an inherited immune defic

110 Chronic granulomatous disease (CGD) is an inherited immunodefici

111 aspergillosis (IA) in patients with chronic granulomatous disease (CGD) is Aspergillus fumigatus fol

112 Chronic granulomatous disease (CGD) is associated with significa

113 Chronic granulomatous disease (CGD) is characterized by overexub

114 Chronic granulomatous disease (CGD) is characterized by recurren

115 Chronic granulomatous disease (CGD) is characterized by severe r

116 Chronic granulomatous disease (CGD) is due to defective nicotina

117 Immunodeficiency in chronic granulomatous disease (CGD) is well characterized.

118 NADPH oxidase 2 (Nox2)-deficient chronic granulomatous disease (CGD) mice that lack the gp91(phox

119 rmal volunteers and in patients with chronic granulomatous disease (CGD) or adenosine deaminase (ADA)

120 inhibited oxidase, or isolated from chronic granulomatous disease (CGD) patients and mice, formed mo

121 Chronic granulomatous disease (CGD) patients are susceptible to

122 Chronic granulomatous disease (CGD) patients have recurrent life

123 hosphate (NADPH) oxidase predisposes chronic granulomatous disease (CGD) patients to infection, and a

124 ide (NADPH) oxidase in patients with chronic granulomatous disease (CGD) results in susceptibility to

125 s and neutrophils from patients with chronic granulomatous disease (CGD) that are completely deficien

126 serious infections in patients with chronic granulomatous disease (CGD) through an unknown mechanism

127 m-negative pathogen in patients with chronic granulomatous disease (CGD), a deficiency in the phagocy

128 B cell compartment in patients with chronic granulomatous disease (CGD), a disorder of phagocyte fun

129 bacterium that infects patients with chronic granulomatous disease (CGD), a primary immunodeficiency

130 prolonged neutropenia or in cases of chronic granulomatous disease (CGD), a primary immunodeficiency

131 hate oxidase 2 (NOX2) function cause chronic granulomatous disease (CGD), a primary immunodeficiency

132 r threat for patients suffering from chronic granulomatous disease (CGD), a primary immunodeficiency

133 her p22(phox) or gp91(phox) leads to chronic granulomatous disease (CGD), a severe immune disorder ch

134 h of which are mouse models of human chronic granulomatous disease (CGD), also lack LTP.

135 Chronic granulomatous disease (CGD), an immunodeficiency with re

136 s in development of gene therapy for chronic granulomatous disease (CGD), an inherited defect in leuk

137 stem cell transplants, patients with chronic granulomatous disease (CGD), and others.

138 ing mutations in this enzyme lead to chronic granulomatous disease (CGD), associated with increased s

139 (HSCT) is a successful treatment for chronic granulomatous disease (CGD), but the safety and efficacy

140 In chronic granulomatous disease (CGD), defective phagocytic nicoti

141 ox), have been described in cases of chronic granulomatous disease (CGD), defining their essential ro

142 ) and lungs of A. fumigatus-infected chronic granulomatous disease (CGD), hydrocortisone-treated, and

143 s from six individuals with X-linked chronic granulomatous disease (CGD), p47phox and p67phox accumul

144 atory burst, ie, from a patient with chronic granulomatous disease (CGD), was strongly inhibited by c

145 red to as NOX2), are associated with chronic granulomatous disease (CGD), which is characterized by r

146 Mutations in gp91(phox) result in chronic granulomatous disease (CGD), which is diagnosed by use o

147 covered, leading to the diagnosis of chronic granulomatous disease (CGD).

148 Wiskott-Aldrich syndrome (WAS), and chronic granulomatous disease (CGD).

149 is the site of mutations in X-linked chronic granulomatous disease (CGD).

150 s is a major threat to patients with chronic granulomatous disease (CGD).

151 has been isolated from patients with chronic granulomatous disease (CGD).

152 n emerging pathogen in patients with chronic granulomatous disease (CGD).

153 people with cystic fibrosis (CF) and chronic granulomatous disease (CGD).

154 ls with the primary immunodeficiency chronic granulomatous disease (CGD).

155 basis for the human immunodeficiency chronic granulomatous disease (CGD).

156 Genetic defects in NADPH oxidase (chronic granulomatous disease [CGD]) and corticosteroid-induced

157 nt, and respiratory burst-deficient (chronic granulomatous disease [CGD]) neutrophils killed Escheric

158 Destructive midline granulomatous disease characterized by necrotizing granu

159 ncies in the oxidative burst seen in chronic granulomatous disease, could lead to pathologic inflamma

160 experience, location in a region endemic for granulomatous disease, country, and practice type were a

161 h Duchenne muscular dystrophy (DMD), chronic granulomatous disease (CYBB), retinitis pigmentosa (RPGR

162 A 28-year-old man with chronic granulomatous disease developed worsening respiratory st

163 G mutations associated with autoimmunity and granulomatous disease did not have altered overall diver

164 ion at the RP3 locus, in addition to chronic granulomatous disease, Duchenne muscular dystrophy (DMD)

165 Granulomatous disease following exposure to Mycobacteriu

166 Sarcoidosis is a chronic granulomatous disease for which there are limited therap

167 ss and death among 287 patients with chronic granulomatous disease from 244 kindreds.

168 A mouse model for chronic granulomatous disease has been developed and promises to

169 Chest imaging was consistent with granulomatous disease in 46.7%.

170 virus (FIPV), which leads to lethal systemic granulomatous disease in cats.

171 tibility factors associated with more severe granulomatous disease in sarcoidosis and CBD.

172 ximately 30 degrees C, so we sought to model granulomatous disease in the ectothermic zebrafish.

173 gene therapy correction of X-linked chronic granulomatous disease in two adult patients was reported

174 arthritis and uveitis in general as well as granulomatous diseases in particular.

175 trophils isolated from patients with chronic granulomatous disease incubated with a caspase inhibitor

176 Chronic granulomatous disease is a rare disorder in which the ph

177 Chronic granulomatous disease is a rare inherited disorder cause

178 Chronic granulomatous disease is a rare inherited primary immuno

179 Chronic granulomatous disease is an inherited immune deficiency

180 Chronic granulomatous disease is caused by missense, nonsense, f

181 Chronic granulomatous disease is the manifestation of genetic de

182 itially conceived as a familial inflammatory granulomatous disease limited to the triad of synovitis,

183 However, chronic granulomatous disease neutrophils, which do not produce

184 Sarcoidosis is a multisystem granulomatous disease of unknown etiology characterized

185 Sarcoidosis is a multisystemic granulomatous disease of unknown etiology that predomina

186 Sarcoidosis is a systemic granulomatous disease of unknown etiology that primarily

187 Sarcoidosis is a multisystem granulomatous disease of unknown etiology that primarily

188 Sarcoidosis is a relatively common systemic granulomatous disease of unknown etiology.

189 Sarcoidosis is a chronic granulomatous disease of unknown etiology.

190 Sarcoidosis is a systemic granulomatous disease of unknown etiology.

191 linical course and pattern of sarcoidosis, a granulomatous disease of unknown origin.

192 gic alveolitis and pulmonary sarcoidosis are granulomatous diseases of the lung for which clinical pr

193 such as Wiskott-Aldrich syndrome and chronic granulomatous disease, offering curative engraftment wit

194 romised patients as well as in patients with granulomatous disease or cystic fibrosis.

195 ox), p47(phox), p67(phox) (autosomal chronic granulomatous disease), or gp91(phox) (X-linked chronic

196 bronchiectasis, autoimmunity, other cancers, granulomatous disease, or previous splenectomy.

197 h compromise p40(phox) function in a chronic granulomatous disease patient, also perturbed class II A

198 fect on endothelial function in NOX2-chronic granulomatous disease patients (-0.9; 95% confidence int

199 d dilatation was not observed in p47-chronic granulomatous disease patients (-1.5%; 95% confidence in

200 Neutrophils from chronic granulomatous disease patients and Lyn -/- mice no longe

201 rrents in granulocytes from X-linked chronic granulomatous disease patients lacking gp91(phox) (X-CGD

202 ed Mo-DC differentiation observed in chronic granulomatous disease patients lacking p22phox.

203 rmally activated in neutrophils from chronic granulomatous disease patients that lack cytochrome b558

204 The response to IR in chronic granulomatous disease patients was compared with that in

205 r NSCLC, secondary pulmonary malignancy, and granulomatous disease patients were 85%, 77%, 73%, and 8

206 Additionally, neutrophils from chronic granulomatous disease patients, carrying mutations in th

207 promise antifungal immune control in chronic granulomatous disease patients.

208 While sarcoidosis is a chronic granulomatous disease presumably reflecting an exaggerat

209 linicopathological presentation of pulmonary granulomatous disease, rats immunized with intravenous (

210 ith the p47(phox) deficiency form of chronic granulomatous disease received intravenous infusions of

211 a feasible option for patients with chronic granulomatous disease, recurrent life-threatening infect

212 Treatment of tuberculosis, a complex granulomatous disease, requires long-term multidrug ther

213 ts and patients with the unrelated pulmonary granulomatous diseases sarcoidosis and berylliosis the s

214 the phagocyte NADPH oxidase complex (chronic granulomatous disease), severe congenital neutropenia (S

215 ovel cytokine that is expressed in pulmonary granulomatous disease such as sarcoidosis and tuberculos

216 hic macrophages constitutes the basis of all granulomatous diseases, such as tuberculosis or sarcoido

217 gene therapy for immunodeficiencies, chronic granulomatous disease, suicide gene therapy for graft-ve

218 eryllium (Be) disease (CBD) is a multisystem granulomatous disease that primarily affects the lung, a

219 Sarcoidosis is a granulomatous disease that primarily affects the lungs a

220 In vivo, MAC manifests as a disseminated granulomatous disease that produces a massive inflammato

221 Mice with chronic granulomatous disease that were infected with B. multivo

222 (phox-/-)) mice are a model of human chronic granulomatous disease; these mice are prone to develop s

223 SCID), Wiskott-Aldrich syndrome, and chronic granulomatous disease through retrospective, prospective

224 nd the susceptibility of humans with chronic granulomatous disease to mycobacterial infection.

225 five children and five adults, with chronic granulomatous disease underwent peripheral-blood stem-ce

226 Survival of patients with chronic granulomatous disease was strongly associated with resid

227 ranswells and cells of patients with chronic granulomatous disease, we show that this downregulation

228 Patients aged 0-40 years with chronic granulomatous disease were assessed and enrolled at the

229 n age 12.7 years; IQR 6.8-17.3) with chronic granulomatous disease were enrolled from June 15, 2003,

230 us disease), or gp91(phox) (X-linked chronic granulomatous disease), which result in variable product

231 OS) because cells from patients with chronic granulomatous disease, which are defective in ROS produc

232 nd in neutrophils from patients with chronic granulomatous disease, which lack NADPH oxidase.

233 as also observed in individuals with chronic granulomatous disease, who lack NADPH oxidase activity b

234 ts with the NADPH oxidase deficiency chronic granulomatous disease, who require antibiotic and antimy

235 age quiescence and prevents mTORC1-dependent granulomatous disease with clinical implications for sar

236 The treatment of chronic granulomatous disease with conventional allogeneic hemat

237 efects in oxidase function result in chronic granulomatous disease with hallmark recurrent microbial

238 6PD deficiency can be a phenocopy of chronic granulomatous disease with regard to the cellular and cl

239 Mice with chronic granulomatous disease (X-CGD mice) generated by mutating

240 established murine model of X-linked chronic granulomatous disease (X-CGD) created by homologous reco

241 used in a clinical trial of X-linked chronic granulomatous disease (X-CGD) gene therapy to achieve tr

242 em cells from patients with X-linked chronic granulomatous disease (X-CGD) give rise to X-CGD-phenoty

243 reviously demonstrated that X-linked chronic granulomatous disease (X-CGD) mice develop exaggerated i

244 nditioning of wild-type and X-linked chronic granulomatous disease (X-CGD) mice.

245 burst (phagocyte oxidase)-deficient chronic granulomatous disease (X-CGD) mice.

246 The X-linked form of chronic granulomatous disease (X-CGD) results from mutations in

247 model, because in mice with X-linked chronic granulomatous disease (X-CGD) that lack oxidase subunits

248 rst oxidase cytochrome b-558, mimics chronic granulomatous disease (X-CGD) to study the role of oxyge

249 (iPSCs) from a patient with X-linked chronic granulomatous disease (X-CGD), a defect of neutrophil mi

250 The X-linked form of chronic granulomatous disease (X-CGD), an inherited deficiency o

251 In HSPCs from patients with X-linked chronic granulomatous disease (X-CGD), caused by mutations in th

252 t in patients and mice with X-linked chronic granulomatous disease (X-CGD).

253 of which cause the X-linked form of chronic granulomatous disease (X-CGD).

254 st-deficient gp91(phox)-/- (X-linked chronic granulomatous disease [X-CGD]) mice and inducible nitric

255 PMNs from individuals with X-linked chronic granulomatous disease (XCGD) do not produce ROS, thereby